Imunovir (Inosine Pranobex)

Inosine Pranobex enhances host immunity by stimulating T‑lymphocyte activity and increasing cytokine production, including interferon‑γ and interleukin‑2. This immunostimulatory effect boosts the body’s natural antiviral defenses, limiting viral replication without directly attacking the virus.

The dosing regimen for Imunovir is determined by the prescribing clinician based on the specific indication, patient age, weight, renal and hepatic function, and other individual factors. Patients should follow the dose and schedule provided by their healthcare professional.

Safety data for Imunovir during pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Imunovir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The primary alternatives for herpes simplex and influenza are nucleoside analogues such as acyclovir or oseltamivir, which act directly on viral enzymes. Imunovir, by contrast, works as an immunomodulator, enhancing the host’s immune response rather than targeting the virus itself, and may be used when adjunctive immune support is desired.

Imunovir should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity.

Imunovir is administered orally. The tablet (or oral formulation) should be swallowed whole with a glass of water, preferably with or after a meal to minimise gastrointestinal discomfort, unless otherwise directed by a healthcare professional.

Serious adverse reactions, although rare, include leukopenia, thrombocytopenia and significant elevations in liver enzymes. Patients should be monitored for signs of infection, unexplained bruising or bleeding, and jaundice, and should report any such symptoms promptly to their physician.

Imunovir should be avoided in individuals with known hypersensitivity to Inosine Pranobex or any excipients in the formulation. Caution is also advised for patients with severe immunodeficiency, uncontrolled liver disease, or those receiving live attenuated vaccines, unless a clinician determines the benefits outweigh the risks.